Gameto Secures Key Harvard IP to Advance Ovary-in-a-Dish Platform and In Vitro Gametogenesis

New updates have been reported about Gameto.

Gameto has deepened its technology position in women’s health by exclusively licensing additional intellectual property from Harvard University covering genetic drivers of meiosis induction in human cells, expanding earlier sponsored research with George Church’s lab and the Wyss Institute. The patent portfolio spans defined gene sets and optimized methods that trigger human cells, including oogonia, to enter early meiotic stages in vitro—an essential step toward generating mature oocytes and advancing human in vitro gametogenesis (IVG). Gameto plans to integrate this meiosis-induction toolkit into its proprietary ovarian organoid, or “ovaroid,” platform, improving its ability to replicate the full spectrum of human ovarian development from induced pluripotent stem cells and strengthening the company’s R&D moat in next-generation fertility solutions.

By extending its ovary-in-a-dish platform to reliably model early meiosis, Gameto enhances its capacity to study historically inaccessible stages of ovarian biology and to run drug discovery programs across multiple indications, including infertility, menopause, and primary ovarian insufficiency. Management describes the expanded IP as materially increasing the scope and power of the ovaroid system, which already combines genetically engineered early germ cells with functional ovarian support cells in a stable developmental niche. The company is layering machine learning and AI tools onto this system for transcription factor-guided differentiation, genetic analysis, and cell profiling, positioning the platform as a scalable engine for therapeutic discovery in women’s health. Backed by $127 million in funding and with its lead program, Fertilo, in Phase 3 clinical trials, this new IP strengthens Gameto’s strategic positioning in IVG and ovarian biology, potentially enabling future treatments for patients unable to produce eggs if IVG is ultimately validated as a safe, regulated clinical option.